DBV Technologies S.A.
DBVTDBV Technologies SA is a publicly owned French biopharmaceutical firm headquartered in Bagneux, France. DBV Technologies is known for developing "Viaskin" technology for administering allergens or antigens to intact skin while avoiding any transfer to the blood. Viaskin Peanut clinical development has received Fast Track designation from the US Food and Drug Administration.
Drugs in Pipeline
6
Phase 3 Programs
4
Upcoming Catalysts
1
Next Catalyst
Aug 4, 2026
21dMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
How DBVT's past catalysts played out
DBV712 250 mcg
Peanut Allergy
Part A Viaskin Peanut 250 mcg
Peanut Allergy
Viaskin Peanut 250 mcg
Peanut Allergy
Viaskin Peanut 250mcg
Peanut Allergy
Viaskin Milk 150 mcg
Food Allergy
Viaskin Peanut 50 mcg
Peanut Allergy
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
DBV712 250 mcg | Phase 3 | Peanut Allergy | - | - |
Part A Viaskin Peanut 250 mcg | Phase 3 | Peanut Allergy | - | - |
Viaskin Peanut 250 mcg | Phase 3 | Peanut Allergy | - | - |
Viaskin Peanut 250mcg | Phase 3 | Peanut Allergy | - | - |
Viaskin Milk 150 mcg | Phase 2 | Food Allergy | - | - |
Viaskin Peanut 50 mcg | Phase 2 | Peanut Allergy | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in DBV Technologies S.A.'s drug pipeline?→
CatalystAlert tracks 6 drug candidates in DBV Technologies S.A.'s (DBVT) pipeline across Phase 3, Phase 2. Its lead program is DBV712 250 mcg (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is DBV Technologies S.A.'s next FDA catalyst?→
DBV Technologies S.A.'s (DBVT) next tracked catalyst is a Earnings expected August 4, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track DBVT biotech catalysts?→
Add DBVT to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow DBV Technologies S.A.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.